Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Chem Biol. 2008 Jan;15(1):70-7. doi: 10.1016/j.chembiol.2007.12.010.

    Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis.

    Source

    Department of Biochemistry, Brandeis University, 415 South Street, Waltham, MA 02454, USA.

    Erratum in

    • Chem Biol. 2008 Feb;15(2):200.

    Abstract

    Cryptosporidium parvum is an important human pathogen and potential bioterrorism agent. No vaccines exist against C. parvum, the drugs currently approved to treat cryptosporidiosis are ineffective, and drug discovery is challenging because the parasite cannot be maintained continuously in cell culture. Mining the sequence of the C. parvum genome has revealed that the only route to guanine nucleotides is via inosine-5'-monophosphate dehydrogenase (IMPDH). Moreover, phylogenetic analysis suggests that the IMPDH gene was obtained from bacteria by lateral gene transfer. Here we exploit the unexpected evolutionary divergence of parasite and host enzymes by designing a high-throughput screen to target the most diverged portion of the IMPDH active site. We have identified four parasite-selective IMPDH inhibitors that display antiparasitic activity with greater potency than paromomycin, the current gold standard for anticryptosporidial activity.

    PMID:
    18215774
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2441818
    Free PMC Article

    Images from this publication.See all images (4)Free text

    Fig. 1
    Fig. 3
    Fig. 2
    Fig. 4

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk